🇺🇸 FDA
Patent

US 9144605

Recombinant rift valley fever virus encoding a dominant-negative inhibitor of DSRNA-dependent protein kinase in the NSS region

granted A61KA61K2039/5254A61K39/12

Quick answer

US patent 9144605 (Recombinant rift valley fever virus encoding a dominant-negative inhibitor of DSRNA-dependent protein kinase in the NSS region) held by The Board of Regents of the University of Texas System expires Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Sep 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/5254, A61K39/12